anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The glomerular filtration barrier, comprising the inner layer of capillary fenestrated endothelial cells, outermost podocytes, and the glomerular basement membrane between them, plays a pivotal role in kidney function. Podocytes, terminally differentiated epithelial cells, are challenging to regenerate once injured. They are essential for maintaining the integrity of the glomerular filtration barrier. Damage to podocytes, resulting from intrinsic or extrinsic factors, leads to proteinuria in the early stages and eventually progresses to chronic kidney disease (CKD). Immune-mediated podocyte injury is a primary pathogenic mechanism in proteinuric glomerular diseases, including minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and lupus nephritis with podocyte involvement. An extensive body of evidence indicates that podocytes not only contribute significantly to the maintenance of the glomerular filtration barrier and serve as targets of immune responses but also exhibit immune cell-like characteristics, participating in both innate and adaptive immunity. They play a pivotal role in mediating glomerular injury and represent potential therapeutic targets for CKD. This review aims to systematically elucidate the mechanisms of podocyte immune injury in various podocyte lesions and provide an overview of recent advances in podocyte immunotherapy. It offers valuable insights for a deeper understanding of the role of podocytes in proteinuric glomerular diseases, and the identification of new therapeutic targets, and has significant implications for the future clinical diagnosis and treatment of podocyte-related disorders.
<P>PROBLEM TO BE SOLVED: To obtain a moisturizing plant extract with sustainable moisture retaining effect for many hours, an external preparation, a cosmetic, a bathing agent and a detergent composition.  <P>SOLUTION: The moisturizing plant extract comprises an extract of a mixture of Zizyphus jujuba Miller var. inermis Rehder, Cinnamomum cassia Blume, Paeonia lactiflora Pallas, Angelica acutiloba Kitagawa, Akebia quinata Decaisne, Glycyrrhiza glabra Linne and Asiasarum sieboldii F. Maekawa. The cosmetic, the bathing agent and the detergent composition each comprises the extract. The product made by decocting a prescribed ratio of the above-mentioned crude medicine has the same composition as that of a medicine called Toukisigyakutou in the traditional Chinese medical science. The extract of the mixture of these crude medicines contains a moisturizing plant component with sustainable moisture retaining effect for many hours and exhibits effects, by external use, on preventing, mitigating or ameliorating dry skin, rough skin, crack, chapped skin, dandruff, itching and inflammatory diseases, and on the hair, in curing dryness, looseness, split hair and broken hair and imparting gloss, and the like.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The present invention relates to the novel cDNA sequence that codes for the B subunit of Crotoxin (Crotoxin B), which is the neurotoxic component of the venom of the crotalid of the southeastern Mexican species called Crotalus tzabcan, expressed by recombinant means and called rCrotoxin B (SEQ. ID NO: 1). Also, it includes the recombinant variant fused with a polypeptide sequence of 19 extra amino acids in its N-terminus, named HisrCrotoxin B (SEQ. ID NO: 2). Additionally, it relates to the cDNA fragment (SEQ. ID NO: 3), which encodes the respective recombinant Crotoxin B in its version: free of the 19 amino acid polypeptide sequence (SEQ. ID NO: 4), comprising the expression constructions for said fragments in expression vectors, and the bacterial cells transformed with said constructions and the recombinant biotechnology method to produce both versions of rCrotoxin B (SEQ. ID NO: 1) and HisrCrotoxin B (SEQ . ID NO: 2). Tests performed allow to demonstrated that HisrCrotoxin B (SEQ. ID NO: 2) is beneficial as an immunogen for producing antibodies against crotalid venom, produced by heterologous expression. Further, it relates to the pharmaceutical compositions of the respective antibodies, particularly to the serotherapeutic and phabotherapeutic agents comprising the use of rCrotoxin B (SEQ. ID NO: 1) and HisrCrotoxin B (SEQ. ID NO: 2) beneficial in the immunopurification of antibodies and their fragments.
The invention relates to the technical field of pharmaceutic adjuvants, in particular to a traditional Chinese medicine for treating respiratory diseases and a preparation method thereof. The composite material comprises the following raw materials in parts by weight: 3-50 parts of radix curcumae, 6-12 parts of fructus epigallocatechin gallate, 5-15 parts of pericarpium citri reticulatae, 3-15 parts of realgar, 5-15 parts of rehmannia, 5-15 parts of poria cocos, 5-15 parts of frankincense, 5-15 parts of radix aucklandiae and 5-15 parts of bulbus fritillariae cirrhosae. Clearing away heat and toxic material, relieving cough, resolving phlegm and relieving asthma. Promoting the circulation of qi and relaxing muscles and tendons, reasonable formula and targeting at the pathogenesis. Can be used alone for treating tracheitis, bronchial asthma, and pneumonia. Can also be matched with an externally-applied pelma medicine for treating suppurative tonsillitis, oral ulcer, acute and chronic pharyngitis and the like, and the cure rate is more than ninety eight percent.
The Recovery Line is an automated computer-based IVR system that provides CBT-based modules. The RL+TAU condition will include the customized therapeutic recommendations developed in Phase 1, and the contact reminders messages and time frame that maximized system use in Phase 2. Patients will receive an orientation, 24-hour access, encouragement to use the system from clinic staff reminder, and technical assistance line for system problems. Patients will receive 12 weeks of system access.
In Morocco, the purpose of the National Cancer Prevention and Control Plan (PNPCC) is to decrease the incidence, mortality, and morbidity attributable to cervical cancer (CC), including the general objective which is to improve women´s care by setting up an organized system for screening, early diagnosis and treatment of this disease, and as operational objectives an: 1) achievement of at least 30% of the annual coverage rate by cervical cancer (CC) screening; 2) achievement of at least 80% of the rate of participation in CC screening per screening cycle; 3) achievement of 100% of the treatment rate for precancerous lesions screened within the framework of the program. CC screening concerns all women aged 30 to 49 years old. Women who have already had CC and pregnant women from the 8th week of amenorrhea until the 6th week postpartum are excluded from the program. The screening test currently used is the naked eye inspection with acetic acid or visual inspection with acetic acid (VIA), which will be followed by a colposcopy exam and biopsy if a precancerous lesion is confirmed. The VIA is carried out at the level of urban and rural health centers, by a trained health professional. Knowing that the pap-smear test was widely used before. Thermo coagulation, also called: cold coagulation, is currently the main treatment for intraepithelial lesions (LIE) that are eligible for this treatment, and finally the national program has introduced anti-HPV vaccination within the national vaccination program (NPI).
The purpose of the present invention is to provide: a skin cosmetic that provides good moist feeling to the skin and good non-stickiness to the skin; and a cosmetic composition that provides good moist feeling to the skin and good non-stickiness to the skin, that has high foamability, and that can be used to obtain a cleanser that is capable of forming fine foam that can be easily washed off. The present invention pertains to a cosmetic composition or the like containing copolymers represented by general formula (1). Regarding the copolymers contained in the cosmetic composition, the average of n + m satisfies 180 ≤ n + m ≤ 350, the average of p + q satisfies 50 ≤ p + q ≤ 90, and a value [asymmetrical coefficient (As)] calculated using the calculation formula (expression 1) below and a chromatogram obtained by measuring a molecular weight distribution of a mixture of the copolymers using gel permeation chromatography under the measurement conditions below is 1.9-4.2. [Measurement conditions for gel permeation chromatography]. Device: HLC-8320GPC (manufactured by Tosoh Corporation). Analysis column: TSKgel Guard column Super AW, TSKgel Super AW4000, TSKgel Super AW3000, and TSKgel Super AW2500 are linked in series (all of the columns are manufactured by Tosoh Corporation, and TSKgel is a registered trademark of Tosoh Corporation). Sample solution: 0.125 wt% of N,N-dimethyl formamide solution. The amount of injected solution: 20 [mu]L. Flow rate: 0.6 mL/min. Measurement temperature: 40 DEG C. Detection device: a refractive index detector [In general formula (1), EO represents an ethyleneoxy group, PO represents a propyleneoxy group, m, n, p, and q each independently represent an integer of at least 0, [(EO)n/(PO)p] represents a polyalkyleneoxy chain in which n mol of ethyleneoxy groups and p mol of propyleneoxy groups are linked in an arbitrarily defined order, and [(EO)m/(PO)q] represents a polyalkyleneoxy chain in which m mol of ethyleneoxy groups and q mol of propyleneoxy groups are linked in an arbitrarily defined order.] As = (R - S)/(T - R) (expression 1) [In this calculation expression (expression 1), R represents an elution time (min) at which a peak (P1) having the highest signal intensity indicates a maximum point on a chromatograph, S and T each represent an elution time (min) at a point at which the signal intensity before or after the maximum point of the peak (P1) becomes 1/10 times the height from the baseline to the maximum point and which is closest to the maximum point, and S < R < T is satisfied.].
An apparatus and methods are disclosed to display information about obtained radiograph images. The displayed information includes a graphic F1 showing the area radiographed by the radiographing apparatus on a body diagram of the human body. The displayed information may also include a scale showing a size of the graphic M1. A posture of the human body at the time it was radiographed may be displayed (figs. 3, 4). A graphic G1 showing the gravity direction relative to the body may be displayed. A medical image list is also displayed. A plurality of indicators F1, F2, F3, F4 for different radiograph images may be displayed at proper positions on the body graphic using different graphics (see fig. 6).
AIM: Our aim was to explore the feasibility of using radiomics data derived from intratumoral and peritumoral edema on fat-suppressed T2-weighted imaging (T2 FS) to distinguish triple-negative breast cancer (TNBC) from non-triple-negative breast cancer (non-TNBC).
METHODS: This retrospective study enrolled 174 breast cancer patients. According to the MRI examination time, patients before 2021 were divided into training (n = 119) or internal test (n = 30) cohorts at a ratio of 8:2. Patients from 2022 were included in the external test cohort (n = 25). Four regions of interest for each lesion were defined: intratumoral regions, peritumoral edema regions, regions with a combination of intratumoral and peritumoral edema, and regions with a combination of intratumoral and 5-mm peritumoral. Four radiomic signatures were built using the least absolute shrinkage and selection operator (LASSO) method after selecting features. Furthermore, a radio mic-radiological model was constructed using a combination of intratumoral and peritumoral edema regions along with clinical-radiologic features. Area under the receiver operating characteristic curve (AUC) calculations, decision curve analysis, and calibration curve analysis were performed to assess the performance of each model.
RESULTS: The radiomic-radiological model showed the highest AUC values of 0.906 (0.788-1.000) and 82.5 (0.622-0.947) in both the internal and external test sets, respectively. The radiology-radiomic model exhibited excellent predictive performance, as evidenced by the calibration curves and decision curve analysis.
CONCLUSION: The ensemble model based on T2 FS-based radiomic features of intratumoral and peritumoral edema, along with radiological factors, performed better in distinguishing TNBC from non-TNBC than a single model. We explored the possibility of developing explainable models to support the clinical decision-making process.
The present invention provides two embodiments. One is a method of testing for compounds which may induce STF-1 transcription. Pancreatic islet cells which express the STF-1/lacZ fusion gene are isolated and the effect of various compounds on STF-1 expression is measured by adding the compound of interest to STF-1/lacZ expressing cells. LacZ activity in control and treated cells is then quantitated by a colorimetric assay. Using this method, a large number of compounds can be screened and STF-1 inducing compounds can be identified readily. The other is a method of using the STF-1 promoter to mark insulin producing pancreatic islet cells in vivo. In this regard, the green fluorescent protein (GFP) served as an indicator. The introduction of the STF-1-green fluorescent protein transgene into pigs allows for the efficient and rapid recovery of insulin producing cells from the pancreas.
This narrative review highlights strategies proposed by the Mexican Group of Experts on Arterial Hypertension endorsed to prevent, diagnose, and treat chronic kidney disease (CKD) related to systemic arterial hypertension (SAH). Given the growing prevalence of CKD in Mexico and Latin America caused by SAH, there is a need for context-specific approaches to address the effects of SAH, given the diverse population and unique challenges faced by the region. This narrative review provides clinical strategies for healthcare providers on preventing, diagnosing, and treating kidney disease related to SAH, focusing on primary prevention, early detection, evidence-based diagnostic approaches, and selecting pharmacological treatments. Key-strategies are focused on six fundamental areas: 1) Strategies to mitigate kidney disease in SAH, 2) early detection of CKD in SAH, 3) diagnosis and monitoring of SAH, 4) blood pressure targets in patients living with CKD, 5) hypertensive treatment in patients with CKD and 6) diuretics and Non-Steroidal Mineralocorticoid Receptor Inhibitors in Patients with CKD. This review aims to provide relevant strategies for the Mexican and Latin American clinical context, highlight the importance of a multidisciplinary approach to managing SAH, and the role of community-based programs in improving the quality of life for affected individuals. This position paper seeks to contribute to reducing the burden of SAH-related CKD and its complications in Mexico and Latin America.
Patients randomized to the ctDNA-based treatment group will have their post-surgery samples analysed directly after informed consent for MEDOCC-CrEATE. Results are reported to the treating physician and patients. All patients with detectable ctDNA are considered high risk stage 2 patients and will be offered adjuvant chemotherapy for 3 months (4 cycles CAPOX) according to routine clinical practice. Patients with undetectable ctDNA will receive routine follow-up at the surgical department.
Participants will receive 20 mg of JNJ-42847922 as a starting dose and matching placebo (1 capsule of 20 mg JNJ-42847922 and 1 capsule of matching placebo) once daily for 14 days. After Day 14, if needed, JNJ-42847922 dose can be increased to 40 mg (2\*20 mg capsules) and flexible dose of JNJ-42847922 (20 or 40 mg) will be taken once daily until Day 167. Dose of JNJ-42847922 (20 or 40 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
Participants received ST1571 100 mg tablets, orally, once daily. Initiated at an oral dose of 200 mg/day for 4 weeks then titrated up to 400 mg/day for 2 weeks followed by 600 mg/day until Week 24, if well tolerated.
Starting dose will be 2.4 g/day (3 tablets/day). Dose increases or decreases of 2.4 g/day (3 tablets/day (1 tablet per meal)) The maximum dose of sevelamer carbonate will be 14.4 g/day (18 tablets/day) and the minimum dose will be 2.4 g/day (3 tablets/day).
The intervention arm switched to oral antibiotics to complete 4 weeks of therapy. Oral antibiotics will be ciprofloxacin (or trimethoprim/sulfamethoxazole if the isolate is resistant).
b -mercaptoethylamine, or bisethylamine disulphide, or salts thereof, or mixtures of these substances are used for the protection of living organisms against the injurious effects of ionizing radiations containing a - and b -particles, g -rays, x-rays, and neutrons. Thus, an injectable solution comprises b -mercaptoethylamine and a salt thereof dissolved in a solvent, e.g. water or propyleneglycol in proportions yielding a pH of 6-8, the weight of the two solids being 2-20 per cent that of the solution.  The propylene glycol solution, for intra-muscular injection, may contain a local anaesthetic, e.g. benzocaine.  The solutions, which may also contain antibiotics, e.g. aureomycin and dihydrostreptomycin and haemostatics, e.g. semicarbazone of adrenochrome, may be supplied in ampoules containing a gas inert towards the solution.  Otherwise, the solid substances may be put up in soluble capsules, pastilles, suppositories &c. or, for external application, may be made up with an excepient, e.g. based on polyethyleneglycol.
This is a small Phase I trial to evaluate the safety of the use as skin test antigens of the immunologically active proteins from the soluble/cytosol and insoluble cell wall of Mycobacterium leprae. The overall objective is to generate new leprosy skin-test antigens, equivalent to tuberculin-PPD in the tuberculosis context, to be used (I) for the early diagnosis of leprosy; and (ii) as epidemiological tools to measure the incidence of disease. Evaluating new leprosy skin test antigens may provide a better way to diagnose leprosy in its early stages of infection. With the early administration of drug therapy, infected individuals can then be cured of this disease before nerve damage occurs or nodules (lepromas) start to develop on the skin. Ten healthy, leprosy-unexposed, tuberculin-negative volunteers, ages 18-40 years old, from within the staff of the Mycobacteria Research Laboratories, Department of Microbiology, Colorado State University, Fort Collins, Colorado, will be selected for this study. The volunteers will be recruited by direct contact after placing notices in the Department of Microbiology at Colorado State University. There are approximately 40 faculty/staff/students in this population and all are routinely tested (PPD skin-testing or chest X-ray) by the staff at the Hartshorn Health Service Center in the context of the Department's tuberculosis research. Five individuals will be selected for testing MLSA-LAM and five will receive MLCwA. Each will receive single 0.1 ml intracutaneous injections of three titrated doses (1, 10 and 25 )lg/ml) of the skin-test antigen, one of mock antigen (i.e., physiological saline), and one of control antigen (the product now in use; Rees MLSA, 10 )lg), divided equally between the subject's two arms. Results will be recorded at 15 min, 48 h, 72 h, and 28 days post-injection. The test dose will be administered with a sterile1 ml syringe calibrated in tenths and fitted with a sterile, one-half inch, 26 or 27 gauge needle. The rubber stopper of the vial will be wiped with a sterile piece of cotton moistened with alcohol and allowed to dry.It is expected that all concentrations of the two leprosy skin test antigens will evoke similar negative responses. If so, all three concentrations will be used for subsequent studies. This protocol is linked to study 98-202.
Disclosed are alicyclic[c]benzopyrone derivatives and use thereof. The alicyclic[c]benzopyrone derivatives are compounds represented by formula I or their salts. The present compounds not only significantly improve high activity induced by MK-801, but also effectively improve clambering symptom induced by Apomorphine and do not cause EPS within effective dose. These  in vitro  targets and  in vivo  pharmacological models are closely related to diseases of the nervous system caused by dopamine dysfunction, especially schizophrenia. Therefore the present compounds can be used for the treatment of central nervous system diseases, especially schizophrenia. ED 50  is lower and effect is stronger in two animal models i.e. high activity induced by MK-801 and clambering symptom induced by Apomorphine, while ED 50  is higher and therapeutic index is greater in animal models of catalepsy.
INTRODUCTION: Vertebral augmentation, including percutaneous vertebroplasty (PVP) or kyphoplasty (PKP), is the current least invasive surgical option and has been widely used to treat the painful osteoporotic vertebral compression fractures (OVCF). However, the postoperative infections could be life-threatening, even though they rarely occur. Our studies aim to clarify the causation and outcomes of spinal infections following augmentation and meanwhile to identify the risk factors.
METHODS: A retrospective study was conducted on patients with OVCF who underwent PVP or PKP, and were subsequently admitted to our institution with postoperative spinal infection between January 2010 and December 2022. A total of 33 patients were finally included.
RESULTS: The rate of spinal infection after augmentation in our single institute was 0.05% (2/3893). In addition to these 2 patients, the remaining 31 were referred from other hospitals. All 33 patients exhibited elevated inflammatory parameters, 14 patients presented with fever, and 9 patients experienced neurological deficits. Additionally, 29 patients had comorbidity and risk factors. Pathogens were identified in 26 patients, while only 7 patients were examined as culture negative. 27 patients underwent revision surgery and 6 patients only received conservative therapy. Anterior surgery was performed in 2 patients, while posterior surgery was performed in 20 patients. A combined anterior-posterior surgery was performed in 5 patients. At the final follow-up, 18 patients had unrestricted mobility, 10 patients required assistance from crutches or a walker for ambulation, 4 patients needed a wheelchair, and 1 patients died after revision surgery.
CONCLUSIONS: Spinal infection after vertebral augmentation is rare, but it cannot be ignored. Surgeons should make every effort to detect the potential preoperative spondylitis or discitis. Once postoperative spinal infection is confirmed, a prompt intravenous antibiotic therapy is warranted. If medication therapy fails, revision surgery involving debridement and spinal reconstruction should be considered.